Scholarlink

<p>Recaticimab (艾心安), a humanised immunoglobulin G1 monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), expands the treatment options available for adults with primary hypercholesterolaemia and mixed dyslipidaemia when used in combination with statins (with or without other lipid-lowering therapies), while also providing an important monotherapy option for patients. It is the only anti-PCSK9 monoclonal antibody approved for use as monotherapy in China. In the phase&#xa0;3 REMAIN trials in adults with hypercholesterolaemia and mixed dyslipidaemia, subcutaneous recaticimab 150&#xa0;mg once every 4&#xa0;weeks and recaticimab 300&#xa0;mg once every 8&#xa0;weeks reduced plasma low-density lipoprotein cholesterol (LDL-C) compared with placebo, with benefits observed at week&#xa0;12 to week&#xa0;48 following treatment initiation. Based on pooled analysis, recaticimab was generally well tolerated, with mostly mild and transient injection site reactions being the most common adverse reaction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recaticimab in primary hypercholesterolaemia and mixed dyslipidaemia: a profile of its use

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Thomas B. Burgess,
  • Hannah A. Blair

摘要

Recaticimab (艾心安), a humanised immunoglobulin G1 monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), expands the treatment options available for adults with primary hypercholesterolaemia and mixed dyslipidaemia when used in combination with statins (with or without other lipid-lowering therapies), while also providing an important monotherapy option for patients. It is the only anti-PCSK9 monoclonal antibody approved for use as monotherapy in China. In the phase 3 REMAIN trials in adults with hypercholesterolaemia and mixed dyslipidaemia, subcutaneous recaticimab 150 mg once every 4 weeks and recaticimab 300 mg once every 8 weeks reduced plasma low-density lipoprotein cholesterol (LDL-C) compared with placebo, with benefits observed at week 12 to week 48 following treatment initiation. Based on pooled analysis, recaticimab was generally well tolerated, with mostly mild and transient injection site reactions being the most common adverse reaction.